BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 9586914)

  • 21. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
    Georgoulias V; Androulakis N; Bouros D; Kouroussis C; Chatzakis K; Papadakis M; Apostopoloulou F; Georgopoulou T; Kotsakis T; Souklakos J; Hatzidaki D; Vlachonikolis J; Panagos G
    Lung Cancer; 1998 Sep; 21(3):213-20. PubMed ID: 9857999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
    Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
    J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
    Mattson K; Vansteenkiste J; Stupp R; Bargetzi M; Saarinen A; Jekunen A; Fillet G; Teixeira M; Gatzemeier U; Olivares R; Soussan-Lazard K; Bérille J
    Anticancer Drugs; 2000 Jan; 11(1):7-13. PubMed ID: 10757557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
    Kosmas C; Tsavaris NB; Malamos NA; Vadiaka M; Koufos C
    J Clin Oncol; 2001 Jan; 19(1):119-26. PubMed ID: 11134204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
    Mattson K; Saarinen A; Jekunen A
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
    Ho JC; Tan EH; Leong SS; Wang CH; Sun Y; Li R; Wahid MI; Jusuf A; Liao M; Guan Z; Handoyo P; Huang JS; Chan V; Luna G; Tsang KW; Lam WK;
    Respir Med; 2003 Jul; 97(7):796-803. PubMed ID: 12854629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
    Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
    Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
    Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
    J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
    Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
    Chemotherapy; 2005 May; 51(2-3):120-5. PubMed ID: 15886471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.